Who Should Get Cord Blood Transplants?

Biology of Blood and Marrow Transplantation

Volumn 13, Issue SUPPL. 1, 2007, Pages 78-82

  Barker, Juliet N ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE;

ALGORITHM; ARTICLE; CLINICAL PROTOCOL; CORD BLOOD STEM CELL TRANSPLANTATION; ENGRAFTMENT; EXPERIMENTAL DESIGN; FEASIBILITY STUDY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HLA MATCHING; HUMAN; LEUKEMIA; LIVING DONOR; MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE CONDITIONING; PATIENT SELECTION; REDUCED INTENSITY CONDITIONING; UNITED STATES; VOLUNTEER;

EID: 33845988031     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.11.001     Document Type: Article

References (25)

1. Kurtzberg J., Laughlin M., Graham M.L., et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 335 (1996) 157-166
2. Gluckman E., Rocha V., Boyer-Chammard A., et al., Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. Outcome of cord blood transplantation from related and unrelated donors. N Engl J Med 337 (1997) 373-381
3. Rubinstein P., Carrier C., Scaradavou A., et al. Outcomes among 562 recipients of placental blood transplants from unrelated donors. N Engl J Med 339 (1998) 1565-1577
4. Wagner J.E., Barker J.N., DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100 (2002) 1611-1618
5. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 102 (2003) 1915-1919
6. Wagner J.E., Kernan N.A., Steinbuch M., et al. Allogeneic sibling umbilical cord blood transplantation in children with malignant and non-malignant disease. Lancet 346 (1995) 214-219
7. Laughlin M.J., Barker J., Bambach B., et al. Hematopoietic engraftment and survival in adult recipients of umbilical cord blood from unrelated donors. N Engl J Med 344 (2001) 1815-1822
8. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 351 (2004) 2265-2275
9. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 351 (2004) 2276-2285
10. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Transplantation of two partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105 (2005) 1343-1347
11. Staba S.L., Escolar M.L., Poe M., et al. Cord blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 350 (2004) 1960-1969
12. Barker J.N., Krepski T.P., DeFor T.E., et al. Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant 8 (2002) 257-260
13. Kernan N.A., Carter S.L., Wagner J.E., et al. Umbilical cord blood transplantation in pediatric patients: results of the prospective multi-institutional Cord Blood Transplantation Study (COBLT). Biol Blood Marrow Transplant 12 (2006) 14
14. Sanz G.F., Saavedra S., Planelles D., et al. Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. Blood 98 (2001) 2332-2338
15. Ooi J., Iseki T., Takahashi S., et al. Unrelated cord blood transplantation for adult patients with de novo acute myeloid leukemia. Blood 103 (2004) 489-491
16. Takahashi S., Iseki T., Ooi J., et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 104 (2004) 3813-3820
17. Barker J.N., Scaradavou A., Stevens C., et al. Analysis of 608 umbilical cord blood (UCB) transplants: HLA match is a critical determinant of transplant-related mortality (TRM) in the post-engraftment period even in the absence of acute graft-vs-host disease (aGVHD). Blood 106 (2005) 92a (abstr.)
18. Eapen M. Unrelated donor hematopoietic stem cell transplantation (HSCT) in children with acute leukemia: risks and benefits of umbilical cord blood (CB) versus HLA-A, -B, -C, and -DRB1 allele-matched bone marrow (BM). Blood 108 11 (2006) 133a
19. Peled T., Mandel J., Goudsmid R.N., et al. Pre-clinical development of cord blood-derived progenitor cell graft expanded ex vivo with cytokines and the polyamine copper chelator tetraethylenepentamine. Cytotherapy 6 (2004) 344-355
20. Robinson S.N., Ng J., Niu T., et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant 37 (2006) 359-366
21. Magro E., Regidor C., Cabrera R., et al. Early hematopoietic recovery after single unit unrelated cord blood transplantation in adults supported by co-infusion of mobilized stem cells from a third-party donor. Haematologica 91 (2006) 640-648
22. Verneris M.R., Brunstein C., DeFor T.E., et al. Risk of relapse after umbilical cord blood transplantation (UCBT) in patients with acute leukemia: marked reduction in recipients of two units. Blood 106 (2005) 93a (abstr.)
23. Brunstein C.G., Weisdorf D.J., Defor T., et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of anti-thymocyte globulin to a non-myeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 108 8 (2006) 2874-2880
24. Brunstein C.G., Barker J.N., DeFor T.E., et al. Non-myeloablative (NMA) umbilical cord blood transplantation (UCBT): promising disease-free survival in 95 consecutive patients. Blood 106 (2005) 166a (abstr.)
25. Barker J.N., DeFor T., Weisdorf D.J., et al. Umbilical cord blood (UCB) transplantation after non-myeloablative (NMA) conditioning for advanced follicular lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia: high incidence of disease-free survival. Blood 106 (2005) 813a (abstr.)